Brown Shipley& Co Ltd Has $6.54 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Brown Shipley& Co Ltd lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,567 shares of the medical research company’s stock after selling 673 shares during the quarter. Thermo Fisher Scientific makes up about 3.2% of Brown Shipley& Co Ltd’s investment portfolio, making the stock its 11th largest position. Brown Shipley& Co Ltd’s holdings in Thermo Fisher Scientific were worth $6,538,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Barrett & Company Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $28,000. FPC Investment Advisory Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $28,000. Missouri Trust & Investment Co acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Pillar Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Finally, Endeavor Private Wealth Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 3.8%

NYSE TMO opened at $397.89 on Thursday. The stock has a 50-day simple moving average of $447.48 and a 200 day simple moving average of $507.46. The company has a market capitalization of $150.20 billion, a PE ratio of 24.07, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm’s revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.11 earnings per share. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

Analysts Set New Price Targets

TMO has been the subject of several research analyst reports. Argus cut their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research report on Tuesday, April 29th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Wednesday, April 23rd. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Finally, Royal Bank of Canada cut their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $607.43.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock worth $7,305,942 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.